ABIVAX Société Anonyme (LON:0RA9)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 4.54B |
| Revenue (ttm) | 8.86M |
| Net Income (ttm) | -155.39M |
| Shares Out | n/a |
| EPS (ttm) | -2.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 377 |
| Average Volume | 885 |
| Open | 69.70 |
| Previous Close | 68.60 |
| Day's Range | 68.30 - 70.30 |
| 52-Week Range | 4.57 - 71.10 |
| Beta | 0.07 |
| RSI | 80.62 |
| Earnings Date | Aug 11, 2025 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.
Financial numbers in EUR Financial StatementsNews
How Hedge Funds Won Big on an Obscure Drugmaker
Results of a Paris company's late-stage drug trial helped turn things around for healthcare-focused funds, which struggled in the first half of the year.
2 Logical Mid-Cap Biotech Buyout Targets
There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on t...
Earnings Outlook For Abivax
Abivax (NASDAQ: ABVX) is set to give its latest quarterly earnings report on Monday, 2025-08-11. Here's what investors need to know before the announcement. Analysts estimate that Abivax will report ...
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-st...
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing ...
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (â¬637.5M) | ABVX Stock News
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or t...
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Compan...
Abivax launches $400M ADS offering
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Co...
Abivax launches $400M U.S. public offering of ADSs
Abivax Announces Launch of Public Offering
Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnolog...
Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Wednesday. The Dow traded up 0.82% to 44,869.16 while the NASDAQ rose 0.16% to 20,925.86. The...
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc . (NYSE: GEV) rose sharply during Wednesday's session after the company posted bette...
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug.
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax shares jump as obefazimod meets key ... Full story available on Benzinga.com
Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis
Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Co...
Abivax reports Q1 results
Abivax Presents First Quarter 2025 Financial Results
Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clini...
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis